If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMortgage Advice Bureau Regulatory News (MAB1)

Share Price Information for Mortgage Advice Bureau (MAB1)

Share Price is delayed by 15 minutes
Get Live Data
532.00    -2.00 (-0.37%)
Bid:
531.00
Ask:
533.00
Spread: 2.00 (0.377%)
Market Cap: £306.51m
MAB1 Live PriceLast checked at - London Stock Exchange

Intraday Mortgage Advice Bureau Share Chart

Trading Update

25 Jan 2024 07:00

RNS Number : 8188A
Mortgage Advice Bureau (Hldgs) PLC
25 January 2024
 

25 January 2024

Mortgage Advice Bureau (Holdings) plc 

("MAB" or the "Group")

Trading Update 

Mortgage Advice Bureau (Holdings) plc (AIM: MAB1) today issues a trading update for the year ended 31 December 2023, ahead of publishing its final results on Tuesday, 19 March 2024.

In September 2023 the Board took a cautious view on expected activity levels for Q4 2023 and hence the outlook for the full year. Actual trading was better than anticipated in Q4 2023 and the Board now expects the Group to report an adjusted profit before tax that is slightly ahead of the current market consensus.

UK Finance's latest estimate of gross new mortgage lending for 2023 is £226bn[1], representing a 28% reduction on 2022. Despite this difficult market, the Group increased its revenue for the year by 4% to circa £239m.

As expected, the total number of advisers at the year-end was down 4% to 2,158[2] (2022: 2,254), including 117 advisers at Fluent, with the average number of mainstream[3] advisers during the year down 2% to 1,940 (2022: 1,988). The number of mainstream advisers at the year-end was down 8% to 1,918 (2022: 2,074).

Current Trading and Outlook

The underlying level of demand for home ownership and home moves remains strong. As the cost of fixed rate mortgages started to reduce at the end of last year, we saw early signs of increased purchase activity as well as re-financing. This pick-up in mortgage volumes has continued into January, with written volumes substantially higher than in January 2023 in the aftermath of the mini-budget. Whilst uncertainty remains in the wider political and geopolitical environment, current trading is encouraging.

MAB remains in a very strong position to capitalise on any market recovery and the inevitable catch-up in house purchase transactions that will follow.

Whilst no organic adviser growth has been assumed for this year, we expect some of our Appointed Representative (AR) firms to resume recruitment earlier than planned if the current momentum continues, with the Group returning to previously achieved levels of adviser growth in 2025. In terms of the addition of new AR firms, activity levels built strongly in H2 2023, and continue to do so. Our delivery of technology, lead generation and retention initiatives are proving compelling, and we expect that to be reflected in our recruitment of new firms this year.

We continued to invest in our proposition throughout 2023, to ensure the strongest possible recovery and continued market share growth in 2024 and beyond. Current trading is encouraging and in line with expectations.

Peter Brodnicki, CEO of MAB, commented:

"2023 was an exceptionally challenging year with consumer confidence heavily impacted, resulting in many customers deciding to delay their house purchase or re-financing.

"Against this difficult backdrop I am very pleased with how MAB has significantly outperformed the market. To ensure we are in the best possible shape when market conditions improve, we have continued to invest across the entire Group to drive lead flow and deliver optimal business and adviser efficiency. There is a great deal to be positive about, and our technology developments and lead initiatives, including the addition of Fluent, have broadened our addressable market and strengthened our growth plans."

Enquiries:

Mortgage Advice Bureau (Holdings) plc +44 (0)1332 525007

Peter Brodnicki, Chief Executive Officer

Ben Thompson, Deputy Chief Executive Officer

Lucy Tilley, Chief Financial Officer

Nominated Adviser and Joint Broker +44 (0)20 7260 1000

Deutsche Numis

Stephen Westgate / Giles Rolls

Joint Broker +44 (0) 20 7418 8900

Peel Hunt LLP

Andrew Buchanan / Mike Burke

 

Media Enquiries:

investorrelations@mab.org.uk

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of UK Domestic Law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR"). 


[1] UK Finance's previous estimate of gross new mortgage lending for 2023, published in December 2022, was £275bn.

[2] Includes a total of 240 advisers at 31 December 2023 who are later life advisers or advisers in directly authorised firms that use MAB's subsidiary, Auxilium, a specialist protection service provider, for protection. For both later life and directly authorised advisers the fees received by MAB represent the net income received by MAB as there are no commission payouts made by MAB.

[3] Excludes directly authorised advisers, later life advisers and advisers from associates in the process of being onboarded under MAB's AR arrangements.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFIDLFISFIS
Date   Source Headline
23rd Dec 20254:25 pmRNSIssuance of Shares and Total Voting Rights
17th Dec 202512:01 pmRNSDirector/PDMR Shareholding
11th Dec 20257:00 amRNSDirectorate changes
4th Dec 20259:25 amRNSStandard form for notification of major holdings
1st Dec 20255:25 pmRNSDirectors' Shareholdings and PDMR notification
18th Nov 20252:11 pmRNSDirectors' Shareholdings and PDMR notification
14th Nov 20257:00 amRNSNotice of Capital Markets Day Update
7th Nov 20255:15 pmRNSHolding(s) in Company
4th Nov 20251:34 pmRNSDirector/PDMR Shareholding
16th Oct 202512:40 pmRNSDirector/PDMR Shareholding
16th Oct 202512:38 pmRNSGrant of Options, PDMR Dealing,Total Voting Rights
30th Sep 20254:43 pmRNSDirector/PDMR Shareholding
25th Sep 20254:30 pmRNSDirector/PDMR Shareholding
23rd Sep 20255:01 pmRNSBlock listing Interim Review
23rd Sep 20257:00 amRNSInterim Results
17th Sep 20252:30 pmRNSDirector/PDMR Shareholding
2nd Sep 20257:00 amRNS-RNotice of HY25 Results and Investor Presentation
29th Aug 20251:13 pmRNSDirector/PDMR Shareholding
27th Aug 20254:26 pmRNSHolding(s) in Company
21st Aug 20253:01 pmRNSDirector/PDMR Shareholding
31st Jul 202511:32 amRNSDirector/PDMR Shareholding
24th Jul 20257:00 amRNSTrading Update
22nd Jul 20255:59 pmRNSEBT Share Purchase
17th Jul 20259:46 amRNSDirector/PDMR Shareholding
16th Jul 20251:58 pmRNSHolding(s) in Company
9th Jul 20259:05 amRNS-RMAB Launches First-Time Buyer Campaign
3rd Jul 20259:54 amRNSDirector/PDMR Shareholding
27th Jun 20253:46 pmRNSNotification of major holdings
19th Jun 20257:00 amRNSBoard Changes
18th Jun 202510:55 amRNSDirector/PDMR Shareholding
11th Jun 202510:18 amRNSHolding(s) in Company
3rd Jun 20252:47 pmRNSDirector/PDMR Shareholding
30th May 20253:52 pmRNSDirector/PDMR Shareholding
22nd May 20257:00 amRNSResults of Annual General Meeting
21st May 20257:00 amRNSAGM Trading Statement
16th May 202512:30 pmRNSDirector/PDMR Shareholding
6th May 202512:37 pmRNSHolding(s) in Company
1st May 20255:19 pmRNSDirectors' Shareholdings and PDMR notification
30th Apr 20255:15 pmRNSGrant of Options, PDMR Dealing and TVR
29th Apr 20258:48 amRNSNotice of AGM
17th Apr 20251:40 pmRNSHolding(s) in Company
16th Apr 20259:58 amRNSDirector/PDMR Shareholding
10th Apr 20257:00 amRNSAppointment of Joint Corporate Broker
4th Apr 20257:10 amRNSAnnual Report and Notice of AGM
1st Apr 20253:51 pmRNSDirector/PDMR Shareholding
27th Mar 20259:18 amRNSHolding(s) in Company
19th Mar 20257:00 amRNSDirectorate Change
18th Mar 20257:00 amRNSFinal Results for the year ended 31 December 2024
17th Mar 20253:40 pmRNSDirector/PDMR Shareholding
14th Mar 20257:00 amRNSBlock Admission Application

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.